BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
Biovitrum and Syntonix set to begin Phase 1/2a clinical trial for the treatment of Hemophilia B
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.